MCID: MCL006
MIFTS: 56

Macular Retinal Edema

Categories: Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Macular Retinal Edema

MalaCards integrated aliases for Macular Retinal Edema:

Name: Macular Retinal Edema 12 15 70
Macular Edema 12 36 54 15
Macular Edema, Cystoid 70
Macular Retinal Oedema 12
Macular Oedema 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4449
KEGG 36 H01651
MeSH 44 D008269
NCIt 50 C35468
SNOMED-CT 67 37231002
UMLS 70 C0024440 C0271051

Summaries for Macular Retinal Edema

KEGG : 36 Macular edema is a common feature of many diseases of the retina, such as intraocular inflammation (uveitis), central or branch retinal vein occlusion, diabetic retinopathy and following cataract extraction. It is characterized by a retinal thickening in the macular area due to the breakdown of the blood-retinal barrier. Extracellular fluid accumulates in the intraretinal area or collects in the subretinal space. In more severe cases, it occurs as cystoid edema with the typical petaloid appearance, and is the leading cause of visual loss. New treatments for macular edema have emerged over the past decade, the most recent and efficacious of which have involved blockage of vascular endothelial growth factor (VEGF) by frequent intravitreal injection of pharmacologic agents.

MalaCards based summary : Macular Retinal Edema, also known as macular edema, is related to diabetic macular edema and central retinal vein occlusion, and has symptoms including edema and peau d'orange. An important gene associated with Macular Retinal Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Dorzolamide and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow... more...

Related Diseases for Macular Retinal Edema

Diseases related to Macular Retinal Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 872)
# Related Disease Score Top Affiliating Genes
1 diabetic macular edema 32.9 VEGFA SERPINF1 PRKCB IL6 ICAM1 CCL2
2 central retinal vein occlusion 32.2 VEGFA SERPINF1 IL6
3 vitreoretinopathy, neovascular inflammatory 32.1 VEGFA CRYAA CCL2
4 macular dystrophy, dominant cystoid 32.0 VEGFA CRYAA CRB1 BEST1 ACE
5 vitreous detachment 31.7 VEGFB VEGFA PGF
6 uveitis 31.4 TNF SERPINF1 IL6 ICAM1 CXCL8 CRYAA
7 retinal vein occlusion 31.4 VEGFA TNF SERPINF1 KDR IL6 CXCL8
8 retinal detachment 31.4 VEGFA TNF SERPINF1 IL6 CXCL8 CXCL12
9 retinal ischemia 31.3 VEGFA TNF CXCL12 CRYAA
10 panuveitis 31.2 TNF IL6 ACE
11 macular holes 31.1 VEGFA SERPINF1 IL6 CXCL8 CRYAA CCL2
12 iridocyclitis 31.1 VEGFA TNF IL6 ACE
13 retinal disease 31.1 CRYAA CRB1 BEST1 ALB
14 microvascular complications of diabetes 5 31.1 VEGFA SERPINF1 PRKCB PGF KDR INS
15 vasculitis 31.0 TNF IL6 ICAM1 CCL2
16 lipid metabolism disorder 31.0 INS IL6 CCL2 ACE
17 papilledema 30.9 VEGFA ALB ACE
18 coats disease 30.9 VEGFA KDR CRB1
19 optic nerve disease 30.9 VEGFA TNF IL6 CRYAA ALB
20 hyperglycemia 30.8 PRKCB INS IL6 ALB
21 retinal vasculitis 30.8 TNF CCL2 ACE
22 senile cataract 30.8 SERPINF1 CRYAA ALB
23 iritis 30.8 VEGFA TNF IL6 ACE
24 microvascular complications of diabetes 3 30.7 INS ALB ACE
25 cataract 30.7 VEGFA TNF SERPINF1 INS IL6 ICAM1
26 poems syndrome 30.7 VEGFA TNF IL6
27 optic neuritis 30.7 VEGFA TNF IL6 CXCL8
28 sympathetic ophthalmia 30.7 TNF ICAM1 CXCL12
29 retinitis pigmentosa 30.7 VEGFA TNF SERPINF1 KDR INS IL6
30 sarcoidosis 1 30.7 TNF ICAM1 CCL2 ACE
31 keratopathy 30.7 TNF ICAM1 CXCL8
32 open-angle glaucoma 30.7 VEGFA TNF IL6 CRYAA ALB ACE
33 acquired immunodeficiency syndrome 30.7 TNF IL6 ICAM1 ALB
34 kuhnt-junius degeneration 30.7 VEGFB VEGFA SERPINF1 PGF KDR FLT1
35 juvenile rheumatoid arthritis 30.6 TNF IL6 CXCL8 CCL2 ALB
36 hemangioma 30.6 VEGFA KDR IL6 FLT1
37 ischemia 30.6 VEGFA KDR ICAM1 FLT1 CXCL12 ACE
38 endophthalmitis 30.6 VEGFB VEGFA TNF PGF IL6 ICAM1
39 eales disease 30.6 VEGFA TNF SERPINF1 IL6
40 proteinuria, chronic benign 30.6 VEGFA INS FLT1 ALB ACE
41 relapsing-remitting multiple sclerosis 30.6 TNF IL6 ICAM1 CXCL8 CCL2
42 neuritis 30.5 VEGFA TNF IL6 CXCL8 CCL2
43 neuropathy 30.5 VEGFA TNF INS IL6 ALB ACE
44 diabetic cataract 30.5 VEGFA SERPINF1 CRYAA
45 macroglobulinemia 30.5 PRKCB IL6 CXCL12
46 choroiditis 30.4 VEGFA TNF ACE
47 hypertensive retinopathy 30.4 VEGFA ALB ACE
48 chorioretinitis 30.4 VEGFA TNF IL6 CRB1 ACE
49 chickenpox 30.4 TNF IL6 ALB
50 neovascular glaucoma 30.4 VEGFB VEGFA PGF KDR FLT1 CXCL8

Graphical network of the top 20 diseases related to Macular Retinal Edema:



Diseases related to Macular Retinal Edema

Symptoms & Phenotypes for Macular Retinal Edema

UMLS symptoms related to Macular Retinal Edema:


edema; peau d'orange

MGI Mouse Phenotypes related to Macular Retinal Edema:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ACE ALB CRB1 CXCL12 FLT1 ICAM1
2 homeostasis/metabolism MP:0005376 10.31 ACE ALB CRB1 FLT1 ICAM1 IL6
3 immune system MP:0005387 10.31 ACE ALB CCL2 CRB1 CXCL12 FLT1
4 hematopoietic system MP:0005397 10.23 ACE CRB1 CXCL12 FLT1 ICAM1 IL6
5 endocrine/exocrine gland MP:0005379 10.18 ACE ALB CRB1 ICAM1 IL6 INS
6 digestive/alimentary MP:0005381 10.1 ALB ICAM1 IL6 INS OCLN SERPINF1
7 muscle MP:0005369 10.02 ALB CXCL12 FLT1 ICAM1 IL6 INS
8 nervous system MP:0003631 10 ACE CRB1 CXCL12 FLT1 ICAM1 IL6
9 liver/biliary system MP:0005370 9.97 ACE ALB CXCL12 IL6 INS KDR
10 neoplasm MP:0002006 9.8 ACE ALB ICAM1 IL6 PGF TNF
11 reproductive system MP:0005389 9.7 ACE BEST1 CXCL12 FLT1 IL6 INS
12 vision/eye MP:0005391 9.44 ACE BEST1 CRB1 FLT1 ICAM1 IL6

Drugs & Therapeutics for Macular Retinal Edema

Drugs for Macular Retinal Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
2
Dipivefrin Approved Phase 4 52365-63-6 3105
3
Timolol Approved Phase 4 26839-75-8 33624 5478
4
Povidone-iodine Approved Phase 4 25655-41-8
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
7
Homatropine Approved Phase 4 87-00-3
8
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
9
Povidone Approved Phase 4 9003-39-8 131751496
10
Iodine Approved, Investigational Phase 4 7553-56-2 807
11
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
12
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
13
Bromfenac Approved Phase 4 91714-94-2 60726
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
16
Travoprost Approved Phase 4 157283-68-6 5282226
17
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
18
Phenylephrine Approved Phase 4 59-42-7 6041
19
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
20
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
25
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
26
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
27
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
28
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
29
Lactitol Approved, Investigational Phase 4 585-86-4 157355
30
Glimepiride Approved Phase 4 93479-97-1 3476
31
Empagliflozin Approved Phase 4 864070-44-0
32
Difluprednate Approved Phase 4 23674-86-4 443936
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
34
Cadexomer iodine Experimental Phase 4 94820-09-4
35
Maleic acid Experimental Phase 4 110-16-7 444266
36
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
37 Carbonic Anhydrase Inhibitors Phase 4
38 Carboxymethylcellulose Sodium Phase 4
39 Neurotransmitter Agents Phase 4
40 Adrenergic Antagonists Phase 4
41 Adrenergic beta-Antagonists Phase 4
42 Antihypertensive Agents Phase 4
43 Adrenergic Agents Phase 4
44 Ketorolac Tromethamine Phase 4
45 Antibiotics, Antitubercular Phase 4
46 Norgestimate, ethinyl estradiol drug combination Phase 4
47 Anti-Infective Agents Phase 4
48 Pyranoprofen Phase 4
49 Dexamethasone 21-phosphate Phase 4
50 Tocolytic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 784)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
2 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
3 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
4 Single Arm, Single Dose Clinical Study to Investigate Efficacy of Treat-and-Extend Regimen of Intravitreal Aflibercept Injection in Diabetic Macular Edema Unknown status NCT02788877 Phase 4 aflibercept
5 Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO Unknown status NCT03892434 Phase 4 Intravitreal bevacizumab and dexamethasone implant Injection
6 A Prospective, Single-Center, Randomized, Double Blind, Double Arm, Comparative Clinical Trial to Compare the Safety and Preliminary Efficacy Between Ranibizumab Monotherapy and Ranibizumab Combined With R:GEN (Selective Retina Therapy) in Clinically Significant Diabetic Macular Edema (a Pilot Study) Unknown status NCT03759860 Phase 4
7 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
8 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
9 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
10 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
11 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
12 The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor Unknown status NCT03475407 Phase 4 Ozurdex intravitreal injection
13 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Unknown status NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
14 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Unknown status NCT03405376 Phase 4 Intravitreal aflibercept injection
15 Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Clinical Trial Unknown status NCT03197480 Phase 4 Aflibercept Injection [Eylea]
16 A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg Unknown status NCT02424019 Phase 4 ILUVIEN 0.19 MG
17 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
18 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
19 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
20 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
21 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
22 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
23 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Unknown status NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
24 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
25 Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion. Completed NCT02478515 Phase 4 Ranibizumab
26 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
27 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
28 Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK) Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
29 An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice Completed NCT01315275 Phase 4 Ranibizumab
30 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
31 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
32 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema. Completed NCT01257815 Phase 4 Ranibizumab
33 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
34 A Randomized Clinical Trial of Intravitreal dexamethasOne Versus Bevacizumab in Aboriginal and Torres Strait Islander patientS With Diabetic Macular Oedema (The OASIS Study) Completed NCT04619303 Phase 4 Dexamethasone intravitreal implant;Bevacizumab Injectable Product
35 A 12-month, Phase IV, Open-label, Randomized, Active Controlled, 2-arm, Multicenter Study Assessing the Efficacy and Safety of Intravitreal Ranibizumab Combined With Grid&Direct Short Pulse Laser Photocoagulation Versus a PRN Ranibizumab Monotherapy in Japanese Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Completed NCT02953938 Phase 4
36 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Completed NCT02274259 Phase 4 Aflibercept;Ranibizumab
37 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
38 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
39 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
40 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
41 A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND) Completed NCT02359526 Phase 4 IlUVIEN
42 Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
43 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
44 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
45 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
46 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
47 Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening Completed NCT00469781 Phase 4 2. Xibrom (Bromfenac);1. Pred Forte
48 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial . Completed NCT02299336 Phase 4 Aflibercept
49 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Completed NCT03097068 Phase 4 Lucentis
50 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium

Search NIH Clinical Center for Macular Retinal Edema

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Flurbiprofen
Flurbiprofen sodium

Genetic Tests for Macular Retinal Edema

Anatomical Context for Macular Retinal Edema

MalaCards organs/tissues related to Macular Retinal Edema:

40
Endothelial, Eye, Retina, Bone Marrow, Cortex, Liver, Pancreas

Publications for Macular Retinal Edema

Articles related to Macular Retinal Edema:

(show top 50) (show all 10305)
# Title Authors PMID Year
1
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 61 54
20232317 2010
2
Visual acuity and foveal thickness after vitrectomy for macular edema associated with branch retinal vein occlusion: a case series. 61 54
20429890 2010
3
[Strategy for treatment of diabetic retinopathy]. 54 61
20387536 2010
4
Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. 54 61
19967679 2010
5
[The possibility of the treatment of bilateral macular edema without the anti VEGF treatment--a case report]. 54 61
20521508 2010
6
Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. 54 61
19815292 2009
7
Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. 61 54
19639332 2009
8
Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. 61 54
19837384 2009
9
Update on treatments of diabetic macular edema. 61 54
19951615 2009
10
Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor. 54 61
18797821 2009
11
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. 61 54
19365011 2009
12
Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. 54 61
19060280 2009
13
Intravitreal bevacizumab for diabetic retinopathy. 61 54
19199897 2009
14
[Topical aspects of etiopathogenesis, medicamentous and laser treatment of branch retinal vein occlusion]. 54 61
19708588 2009
15
Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. 61 54
19118700 2009
16
Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. 54 61
19118699 2009
17
Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. 61 54
18988180 2008
18
Retinal vascular occlusions: an interdisciplinary challenge. 54 61
19626196 2008
19
Regulation of retinal blood flow in health and disease. 61 54
18448380 2008
20
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. 61 54
18362932 2008
21
Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. 61 54
18293182 2008
22
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). 54 61
17674014 2008
23
PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema. 54 61
18421240 2008
24
Seeing the light: new insights into the molecular pathogenesis of retinal diseases. 61 54
17654481 2007
25
Bevacizumab in retinal vein occlusion-results of a prospective case series. 61 54
17356824 2007
26
Targeted pharmacotherapy of retinal diseases with ranibizumab. 61 54
17925884 2007
27
Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. 61 54
17513698 2007
28
[Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. 54 61
17372737 2007
29
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. 61 54
17420693 2007
30
Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema. 54 61
17564928 2007
31
The therapeutic potential of VEGF inhibition in diabetic microvascular complications. 61 54
18076206 2007
32
Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. 54 61
17167405 2006
33
[Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. 54 61
16763863 2006
34
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. 54 61
16133018 2006
35
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. 61 54
16086947 2005
36
Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. 61 54
15793254 2005
37
The potential role of PKC beta in diabetic retinopathy and macular edema. 54 61
12507628 2002
38
Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. 61 54
12160804 2002
39
Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. 54 61
11992868 2002
40
Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. 54 61
11755841 2002
41
Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. 54 61
9227268 1997
42
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. 61 54
9046048 1997
43
Up-regulation of vascular endothelial growth factor production by iron chelators. 61 54
8706019 1996
44
Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study. 61
33130144 2021
45
Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study. 61
33789617 2021
46
Choroidal thickening in retinal vein occlusion patients with serous retinal detachment. 61
33205242 2021
47
Outcomes and complications of Boston keratoprosthesis type I implantation in unilateral versus bilateral corneal blindness. 61
33002416 2021
48
AQUEOUS HUMOR CYTOKINE LEVELS AND REBOUND MACULAR EDEMA AFTER CONBERCEPT TREATMENT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION. 61
33755650 2021
49
MICROSTRUCTURAL CHANGES IN CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA AFTER INTRAVITREAL DEXAMETHASONE IMPLANT INJECTION. 61
32796442 2021
50
Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema. 61
32997288 2021

Variations for Macular Retinal Edema

Expression for Macular Retinal Edema

Search GEO for disease gene expression data for Macular Retinal Edema.

Pathways for Macular Retinal Edema

Pathways related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VEGFB TNF SERPINF1 PRKCB PGF KDR
2
Show member pathways
13.88 VEGFB VEGFA TNF PRKCB PGF KDR
3
Show member pathways
13.74 TNF SERPINF1 PRKCB KDR INS IL6
4
Show member pathways
13.51 VEGFB VEGFA TNF PGF KDR INS
5
Show member pathways
13.47 VEGFA PRKCB OCLN KDR ICAM1 CXCL8
6
Show member pathways
13.46 VEGFB TNF PRKCB PGF KDR IL6
7
Show member pathways
13.37 VEGFB PRKCB PGF KDR IL6 FLT1
8
Show member pathways
13.34 VEGFB VEGFA TNF PRKCB PGF KDR
9
Show member pathways
13.3 VEGFB TNF PRKCB PGF KDR IL6
10
Show member pathways
13.27 TNF PRKCB OCLN IL6 ICAM1 CXCL8
11
Show member pathways
13.13 VEGFB PRKCB PGF KDR IL6 FLT1
12
Show member pathways
13.04 VEGFB VEGFA TNF PGF KDR INS
13
Show member pathways
12.97 VEGFA TNF PRKCB IL6 ICAM1 CXCL8
14
Show member pathways
12.96 VEGFB VEGFA PRKCB PGF KDR FLT1
15
Show member pathways
12.93 VEGFA TNF INS IL6 ICAM1 CXCL8
16 12.92 VEGFB VEGFA PRKCB PGF IL6 CXCL8
17
Show member pathways
12.9 VEGFB PRKCB PGF KDR INS IL6
18
Show member pathways
12.89 TNF PRKCB IL6 ICAM1 CXCL8 CCL2
19
Show member pathways
12.81 VEGFB VEGFA PRKCB PGF KDR INS
20 12.78 VEGFB VEGFA TNF PRKCB PGF KDR
21
Show member pathways
12.7 VEGFB TNF PRKCB PGF KDR IL6
22
Show member pathways
12.69 VEGFA PRKCB OCLN KDR ICAM1 CXCL12
23
Show member pathways
12.58 TNF PRKCB KDR INS FLT1
24
Show member pathways
12.57 VEGFB VEGFA PRKCB KDR FLT1
25
Show member pathways
12.5 VEGFB VEGFA PRKCB PGF KDR FLT1
26
Show member pathways
12.47 VEGFB PGF KDR IL6 FLT1 CXCL12
27
Show member pathways
12.47 VEGFA PRKCB KDR ICAM1 CCL2
28 12.46 VEGFB VEGFA PRKCB KDR FLT1
29
Show member pathways
12.41 TNF IL6 CXCL8 CXCL12 CCL2
30
Show member pathways
12.39 TNF INS IL6 ICAM1 CCL2 ALB
31
Show member pathways
12.38 TNF IL6 CXCL8 CCL2
32 12.35 VEGFA TNF PRKCB KDR
33 12.29 TNF IL6 CXCL8 CCL2
34 12.24 VEGFA TNF IL6 CXCL8
35 12.18 VEGFA TNF KDR ICAM1 CCL2
36 12.15 TNF IL6 CXCL8 CCL2
37 12.15 VEGFA KDR INS IL6 ALB
38
Show member pathways
12.12 VEGFB TNF PRKCB PGF KDR IL6
39 12.1 TNF IL6 ICAM1 CXCL8 CCL2
40 12.05 TNF IL6 ICAM1 CCL2
41
Show member pathways
12.04 TNF PRKCB INS IL6
42 12.03 VEGFA PRKCB INS IL6 FLT1
43 12 TNF PRKCB IL6 CXCL8
44 12 TNF PRKCB ICAM1 CXCL8 CXCL12
45 11.94 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
46 11.93 VEGFB KDR FLT1 CCL2
47
Show member pathways
11.91 VEGFB VEGFA PGF KDR FLT1
48 11.8 TNF IL6 CXCL8
49 11.76 TNF IL6 CXCL8 CCL2
50 11.74 TNF IL6 ICAM1

GO Terms for Macular Retinal Edema

Cellular components related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 VEGFB VEGFA TNF SERPINF1 PGF KDR
2 extracellular space GO:0005615 9.47 VEGFB VEGFA TNF SERPINF1 PGF INS
3 platelet alpha granule lumen GO:0031093 9.33 VEGFB VEGFA ALB

Biological processes related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 VEGFB VEGFA PRKCB PGF INS IL6
2 immune response GO:0006955 10.1 TNF IL6 CXCL8 CXCL12 CCL2
3 negative regulation of apoptotic process GO:0043066 10.09 VEGFB VEGFA KDR IL6 CRYAA ALB
4 positive regulation of gene expression GO:0010628 10.08 VEGFA TNF OCLN INS IL6 CXCL8
5 positive regulation of cell proliferation GO:0008284 10.07 VEGFA PGF KDR INS IL6 FLT1
6 positive regulation of cell migration GO:0030335 9.99 VEGFA KDR INS FLT1 CXCL12
7 cytokine-mediated signaling pathway GO:0019221 9.99 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
8 positive regulation of protein kinase B signaling GO:0051897 9.97 VEGFB VEGFA TNF INS
9 positive regulation of protein phosphorylation GO:0001934 9.97 VEGFB VEGFA TNF PGF KDR
10 response to hypoxia GO:0001666 9.96 VEGFB VEGFA PGF ICAM1 CXCL12
11 chemotaxis GO:0006935 9.95 FLT1 CXCL8 CXCL12 CCL2
12 cellular response to lipopolysaccharide GO:0071222 9.95 TNF IL6 ICAM1 CXCL8 CCL2
13 regulation of cell shape GO:0008360 9.93 VEGFA KDR ICAM1 CCL2
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF PRKCB INS IL6 ICAM1
15 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 VEGFB VEGFA TNF KDR ICAM1 CCL2
16 cellular response to tumor necrosis factor GO:0071356 9.92 OCLN ICAM1 CXCL8 CCL2
17 positive regulation of MAPK cascade GO:0043410 9.89 VEGFA KDR INS IL6 FLT1
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 VEGFB VEGFA IL6 ICAM1
19 chemokine-mediated signaling pathway GO:0070098 9.87 CXCL8 CXCL12 CCL2
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 VEGFA TNF IL6
21 angiogenesis GO:0001525 9.87 VEGFB VEGFA PGF KDR FLT1 CXCL8
22 negative regulation of gene expression GO:0010629 9.86 VEGFB VEGFA TNF SERPINF1 OCLN KDR
23 positive regulation of MAP kinase activity GO:0043406 9.85 VEGFA TNF FLT1
24 humoral immune response GO:0006959 9.85 TNF IL6 CCL2
25 positive regulation of cell adhesion GO:0045785 9.85 VEGFA TNF CXCL12
26 positive regulation of cell division GO:0051781 9.83 VEGFB VEGFA PGF
27 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 VEGFA TNF KDR INS FLT1
28 positive chemotaxis GO:0050918 9.82 VEGFB VEGFA PGF
29 monocyte chemotaxis GO:0002548 9.81 IL6 FLT1 CCL2
30 protein kinase B signaling GO:0043491 9.8 TNF KDR CCL2
31 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFB VEGFA PGF KDR CXCL12
32 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.79 VEGFA KDR FLT1
33 sprouting angiogenesis GO:0002040 9.78 VEGFB VEGFA PGF
34 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.77 VEGFB VEGFA PGF KDR FLT1
35 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.74 TNF IL6 ICAM1
36 neutrophil mediated immunity GO:0002446 9.7 IL6 ACE
37 positive regulation of angiogenesis GO:0045766 9.7 VEGFB VEGFA PRKCB PGF KDR FLT1
38 negative regulation of lipid storage GO:0010888 9.69 TNF IL6
39 vascular wound healing GO:0061042 9.69 VEGFA KDR
40 regulation of glucose transmembrane transport GO:0010827 9.69 PRKCB OCLN
41 positive regulation of axon extension involved in axon guidance GO:0048842 9.68 VEGFA CXCL12
42 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
43 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.66 VEGFA ACE
44 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.66 VEGFA KDR
45 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.65 VEGFA KDR
46 positive regulation of mast cell chemotaxis GO:0060754 9.65 VEGFB VEGFA PGF
47 vascular endothelial growth factor signaling pathway GO:0038084 9.35 VEGFB VEGFA PGF KDR FLT1
48 induction of positive chemotaxis GO:0050930 9.02 VEGFB VEGFA PGF CXCL8 CXCL12

Molecular functions related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.03 VEGFB VEGFA TNF KDR INS CRYAA
2 growth factor activity GO:0008083 9.55 VEGFB VEGFA PGF IL6 CXCL12
3 chemokine activity GO:0008009 9.54 CXCL8 CXCL12 CCL2
4 chemoattractant activity GO:0042056 9.5 VEGFB VEGFA PGF
5 cytokine activity GO:0005125 9.43 VEGFA TNF IL6 CXCL8 CXCL12 CCL2
6 vascular endothelial growth factor-activated receptor activity GO:0005021 9.4 KDR FLT1
7 vascular endothelial growth factor receptor 1 binding GO:0043183 9.26 VEGFB VEGFA
8 vascular endothelial growth factor receptor binding GO:0005172 8.8 VEGFB VEGFA PGF

Sources for Macular Retinal Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....